This guide outlines essential postmarket cybersecurity strategies for medical device manufacturers to maintain FDA compliance, protect patient safety, and minimize business impact from emerging threats. It emphasizes continuous monitoring, proactive vulnerability management, and robust incident response planning to secure devices throughout their operational lifecycle.
Every CVE deserves a recorded outcome — even "not affected" — to satisfy FDA postmarket expectations.
Utilize automated tools to continuously track your Software Bill of Materials (SBOM) for all devices. This helps detect vulnerabilities in third-party and open-source components as soon as they are identified, enabling proactive responses.
Set up systems to actively monitor cyber threats across your device ecosystem and receive instant notifications for CVEs affecting your devices. This allows for rapid mitigation before threats impact device functionality or patient safety.
Create and regularly update proven incident response playbooks tailored for medical device patient-safety scenarios. These plans should minimize downtime, ensure audit-ready documentation, and protect both patients and your brand during a cybersecurity incident.
Implement tailored risk mitigation strategies for older devices that may not be patchable. Focus on compensating controls to extend their lifecycle while balancing safety, functionality, and compliance.
Generate audit-ready reports and exportable evidence that align with FDA postmarket guidance for all cybersecurity activities. This simplifies compliance and streamlines the audit process.
Perform annual penetration testing and static application security testing (SAST) on your full device and ecosystem. This proactively identifies vulnerabilities and weaknesses before they can be exploited.
Implement a process to assess each identified cybersecurity vulnerability within its clinical context, integrating ISO 14971 risk management principles. Prioritize remediation steps based on potential patient safety impact.
Utilize a secure dashboard to track vulnerabilities, patches, and incidents in real-time. This provides full visibility and simplifies the management of your postmarket security posture.
Authoritative guidance and standards underpinning this topic. Always confirm the latest revision with the publisher.
Quick answers to the questions teams most often ask about this topic.
Manufacturers must monitor for new vulnerabilities affecting their device or its components, assess risk, develop and deploy patches, coordinate disclosure, and report certain vulnerabilities to the FDA. Section 524B, the FDA's 2026 premarket cybersecurity guidance, and the 2016 postmarket cybersecurity guidance together set the expectations.
When it represents an uncontrolled risk that could cause serious harm or death, or when remediation cannot be deployed quickly enough to keep risk acceptable. The FDA's 2016 postmarket guidance defines the criteria and timelines.
CVD is the published process by which security researchers can report vulnerabilities to your team, get acknowledgment, and coordinate public disclosure timing. The FDA expects every cyber device manufacturer to have a CVD process and contact published.